Mirion Technologies, Inc. reports company developments in radiation detection, measurement, analysis and monitoring solutions for nuclear, medical, defense and research markets. Updates commonly cover financial results, orders, guidance, investor presentations and leadership appointments across the Nuclear & Safety and Medical groups.
Mirion's recurring business themes include nuclear power customers, critical radiation safety applications, R&D labs, nuclear facilities and healthcare uses such as Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry and Diagnostic Imaging. News also reflects the completed Paragon Energy Solutions acquisition, which added engineered nuclear-power offerings and is being integrated into the Nuclear & Safety group.
On October 21, 2022, Sun Nuclear, a subsidiary of Mirion Technologies (NYSE: MIR), announced its participation in the ASTRO Annual Meeting, showcasing its enhanced Quality Management portfolio. Key exhibits include the SunCHECK Platform and the new SunSCAN 3D System, designed for precise dosimetry and efficient workflows in radiation therapy. Sun Nuclear emphasizes its commitment to patient safety, supporting over 1,600 global clinical users with advanced QA solutions. The event runs from October 23-25, 2022, in San Antonio, Texas, where attendees can participate in demonstrations and networking sessions.
Sun Nuclear, a subsidiary of Mirion Technologies (NYSE: MIR), announced the development of new Quality Management solutions in collaboration with Accuray for the Radixact® System with Synchrony®. These innovations will be showcased at the ASTRO Annual Meeting from October 23-25, 2022. Key offerings include the Enhanced Dynamic Platform, designed for precise tumor treatment, and the MotionCHECK™ 3D System, enhancing tumor tracking capabilities. These tools aim to improve patient safety and quality assurance in advanced radiation therapy.
Mirion Technologies has appointed Michael Rossi as the new President of Mirion Medical, reporting directly to CEO Tom Logan. Rossi, with extensive experience from Novartis and other companies, aims to leverage his expertise in nuclear medicine to boost organic and inorganic growth within the company. Logan expressed confidence in Rossi's leadership abilities, highlighting the exciting growth opportunities ahead for Mirion. The company, headquartered in Atlanta, is a leading provider of radiation detection and analysis solutions, employing around 2,800 personnel across 13 countries.
Mirion Technologies, Inc. (NYSE: MIR) announced that its subsidiary, Sun Nuclear, achieved ISO/IEC 27001:2013 certification for its information security management system. This certification confirms Sun Nuclear's compliance with international standards for managing sensitive data across its facilities in the U.S., Germany, and the Netherlands. It also applies to the SunCHECK® Platform, enhancing software reliability and security. This distinction positions Sun Nuclear as a leading QA provider in the Radiation Oncology field, reinforcing its commitment to customer data protection.
Mirion Technologies, Inc. (NYSE: MIR) announces the appointment of Dr. Sheila Rege, M.D. to its Board of Directors, succeeding Mr. Christopher Warren. Dr. Rege, a board-certified radiation oncologist with over 30 years of experience, will support Mirion's strategy to enhance its Medical segment, aiming for 50% of total revenue. Chairman Lawrence D. Kingsley expressed confidence in her contributions to the company’s growth. Chris Warren leaves with commendations for his role in Mirion's evolution since 2015, emphasizing strong demand momentum in the market.
Sun Nuclear, a subsidiary of Mirion Technologies (NYSE: MIR), announced that its ATOM® Phantom product line will participate in NASA's historic Artemis I mission, set to launch on August 29, 2022. Two custom ATOM Phantoms, named Helga and Zohar, will measure potential radiation exposure for astronauts aboard the Orion spacecraft. This mission marks an important step for human exploration of the Moon and Mars. The ATOM Phantoms, designed to simulate human anatomy, will assist in understanding the effects of space radiation, particularly on female astronauts.
Mirion Technologies (NYSE: MIR) has completed the acquisition of the Critical Infrastructure business from Collins Aerospace, specifically through its subsidiary ARINC Incorporated. This acquisition aims to enhance Mirion's capabilities in command-and-control software solutions, particularly for nuclear power facilities and government security. The new division, branded as Secure Integrated Solutions (SIS), is expected to bolster Mirion's digital solutions for its industrial clients, leveraging the expertise of the acquired team in software development.
Mirion Technologies, Inc. (NYSE: MIR) reported a 2.3% decline in second-quarter revenues to $175.8 million, with a net loss of $59.3 million. Adjusted EBITDA fell 14.6% to $42.6 million, and adjusted EPS was $0.13. The company confirmed its 2022 expectations for organic adjusted revenue growth of 4%-6% and adjusted EBITDA of $170-$180 million. Order growth reached 25% in the first half, with a backlog of $693 million, despite a $55 million impairment due to project cancellations related to the Russia-Ukraine conflict.
Mirion Technologies, Inc. (NYSE: MIR) announced that CEO Thomas Logan and CFO Brian Schopfer will present at the Jefferies Industrials Conference in New York, NY, on Wednesday, August 10, 2022, at 1:00 PM ET. The presentation will be available via a live webcast, which can be accessed on their website under the 'Events and Presentations' section. An archived version will be posted within 12 hours post-event and will remain accessible for at least two weeks. Mirion specializes in detection and monitoring solutions across various end markets.
Mirion Technologies, Inc. (NYSE: MIR) will release its financial results for the second quarter of 2022 on Friday, July 29, 2022. The company will hold a conference call at 10:00 am ET to discuss these results. Interested participants can join the call by dialing 1-877-407-9208 or 1-201-493-6784. A live webcast will also be available on the Mirion investor relations website. A telephonic replay will be accessible until August 12, 2022.